系统性红斑狼疮患者抗β2-糖蛋白Ⅰ抗体检测及其临床意义

目的 探求抗β2-糖蛋白Ⅰ(β2glyeoprotein Ⅰ,β2-GP Ⅰ抗体IgG、IgA、IgM在系统性红斑狼疮(SLE)临床的测定.方法 采用酶联免疫吸附试验(ELISA)检测100例SLE患者、39例疾病对照组(包括类风湿关节炎、硬化症、干燥综合征、自身免疫性肝病和混合性结缔组织病)和30例正常人群血清抗β2-GP 1抗体、抗心磷脂抗体(ACL)IgC、IgA、IgM等指标,分析其与临床特点(如血栓、流产)的关系.结果 SLE组抗β2-GP Ⅰ抗体(IgG、IgA、IgM)浓度高于正常对照组,差异具有统计学意义(P<0.01),敏感性、特异性、阳性预测值、阴性预测值分别为17.2%、95.7%、85.0%、44.6%.β2-GPⅠ抗体(IgG、IgA、IgM)与ACL抗体(IgG、IgA、IgM)两者呈正相关(r值分别为0.418、0.624、0.518、0.583,P<0.01).以SLE DAI为因变量对β2-GPⅠ抗体、ACL抗体、dsDNA、u1-RNP、Sm、SSA、SSB、Sc1-70、Jo-1、P.蛋白、PT、APTT进行Logistic回归统计分析,入选的自变量有β2-GPⅠ·IgC和dsDNA.结论 抗β2GP Ⅰ抗体在SLE中具有一定敏感性和较高的特异性,与SLE的血栓形成相关,且抗β2-CPⅠ抗体IgG是SLE疾病活动性危险因素之一.检测抗β2-GPⅠ抗体在SLE中存在一定临床应用价值.

Clinical significance of anti-β2glycoprotein I antibodies in systemic lupus erythematosus

Objective To investigate the clinical application of anti-β2 glyeoprotein Ⅰ antibodies (IgG, IgM, IgA)in systemic lupus erythematosus(SLE). Methods The anti-β2-GP Ⅰ antibodies and anti-cardiolipin antibodies(ACL) level were measured by ELISA in 100 SLE patients, 39 other rheumatoid arthri-tis patients and 30 healthy control people. Their clinical application was analyzed in SLE diagnose and thera-py. Results The level of anti-β2-GP Ⅰ (IgG, IgM, IgA)were significantly higher in SLE than that in healthy (P < 0. 01 ). Sensitivity, specificity, positive predictive value and negative predictive value were 17.2%, 95.7%, 85.0% and 44. 6%, respectively. There was a significant and positive correlation be-tween anti-β2-GP Ⅰ antibodies and ACL antibodies ( IgG, IgM, IgA) (r = 0.418, 0. 624, 0.518, 0. 583, P <0.01). In multivariate analysis the factors(anti-β2-GP Ⅰ antibodies, ACL antibodies, dsDAN, u1-RNP, Sm, SSA, SSB, Jo-1, Scl-70, P-protein, PT, APTT) associated with SLE disease activity index(SLEDAI) were anti-β2-GP Ⅰ (IgG) and dsDNA. Conclusion anti-β2-GP Ⅰ antibody has high specificity and positive predict value, also is associated with SLE's thrombosis. It has some values in the clinical application.